Leukemia research最新文献

{"title":"Epidemiological and genetic insights into the co-occurrence of cutaneous melanoma and hematologic malignancies: A meta-analytic review","authors":"Ashmitha Kumar,&nbsp;Arunan Jeyakumar,&nbsp;Alfred K. Lam,&nbsp;Vinod Gopalan","doi":"10.1016/j.leukres.2024.107610","DOIUrl":"10.1016/j.leukres.2024.107610","url":null,"abstract":"<div><h3>Background</h3><div>The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).</div></div><div><h3>Aim</h3><div>This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.</div></div><div><h3>Methodology</h3><div>A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics.</div><div>The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).</div></div><div><h3>Results</h3><div>Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.</div></div><div><h3>Conclusion</h3><div>This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107610"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546252","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In vitro testing of drug response in primary multiple myeloma cells using a microwell-based technology","authors":"Josefine Krüger ,&nbsp;Igor Wolfgang Blau ,&nbsp;Olga Blau ,&nbsp;Alice Bettelli ,&nbsp;Laura Rocchi ,&nbsp;Massimo Bocchi ,&nbsp;Jan Krönke ,&nbsp;Lars Bullinger ,&nbsp;Ulrich Keller ,&nbsp;Axel Nogai","doi":"10.1016/j.leukres.2024.107599","DOIUrl":"10.1016/j.leukres.2024.107599","url":null,"abstract":"<div><div>Multiple myeloma is an aggressive neoplasm of plasma cells. While numerous drugs have gained approval, the absence of established predictive markers for individual drug responses poses a challenge. In this study, we explored the microwell- and fluorescence-based Cellply CC-Array® technology for high-throughput analysis of <em>in vitro</em> drug responses as a potential predictive marker for patient treatment outcomes. Furthermore, we investigated its application for evaluating effector cell effectiveness. Mononuclear cells were isolated from the bone marrow of 22 patients, and <em>in vitro</em> drug response of primary myeloma cells was analyzed. <em>In vitro</em> responses towards melphalan, bortezomib, and dexamethasone in primary patient samples correlated with clinical response of the patients. The approach exhibited limitations in identifying sensitivity towards lenalidomide, daratumumab, and elotuzumab due to limited culturing time caused by poor myeloma viability <em>in vitro</em>. Through the analysis of cell proximity, the platform enabled the assessment of individual anti-tumor activity from NK and T cells. In summary, the CC-Array microwell technology allowed assessment of myeloma cell responses to selected drugs used in multiple myeloma therapy <em>in vitro</em>. To further validate these <em>in vitro</em> results against <em>in vivo</em> outcomes, screening a larger cohort is necessary.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107599"},"PeriodicalIF":2.1,"publicationDate":"2024-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effect of body mass index on the safety of bosutinib in patients with chronic leukemia: A post hoc pooled data analysis","authors":"Susanne Isfort,&nbsp;Carlo Gambacorti-Passerini,&nbsp;Tim H. Brümmendorf,&nbsp;B. Douglas Smith,&nbsp;Simon Purcell,&nbsp;Maja Strecker,&nbsp;Huadong Zhao,&nbsp;Luke Kuttschreuter,&nbsp;Jane Apperley","doi":"10.1016/j.leukres.2024.107609","DOIUrl":"10.1016/j.leukres.2024.107609","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107609"},"PeriodicalIF":2.1,"publicationDate":"2024-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142546253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of ruxolitinib in real-world patients with myelofibrosis: A 2-year observational study from Taiwan","authors":"Ming-Chung Kuo ,&nbsp;Chien-Chin Lin ,&nbsp;Hsuan-Yu Lin,&nbsp;Jyh-Pyng Gau,&nbsp;Ming-Chung Wang,&nbsp;Ming-Chih Chang,&nbsp;Tsung-Chih Chen,&nbsp;Shih-Peng Yeh,&nbsp;Yeu-Chin Chen,&nbsp;Cih-En Huang,&nbsp;I-Ju Chiang,&nbsp;Hao-Wei Cheng,&nbsp;Yee-Ming Lee,&nbsp;Fan-Chen Ku,&nbsp;Cheng-Shyong Chang","doi":"10.1016/j.leukres.2024.107601","DOIUrl":"10.1016/j.leukres.2024.107601","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107601"},"PeriodicalIF":2.1,"publicationDate":"2024-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142564418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The phylogenetic age paradox of non-coding RNAs","authors":"Martin S. Staege","doi":"10.1016/j.leukres.2024.107600","DOIUrl":"10.1016/j.leukres.2024.107600","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107600"},"PeriodicalIF":2.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase I study of the myeloid cell leukemia 1 (MCL1) inhibitor tapotoclax (AMG 176) in patients with myelodysplastic syndromes after hypomethylating agent failure","authors":"Kelly S. Chien,&nbsp;Juan Jose Rodriguez-Sevilla,&nbsp;Yesid Alvarado,&nbsp;Guillermo Montalban-Bravo,&nbsp;Danielle E. Hammond,&nbsp;Mahesh Swaminathan,&nbsp;Alexandre Bazinet,&nbsp;Jacqueline Kimberley,&nbsp;Kristy Bodden,&nbsp;Heather Schneider,&nbsp;Xiao Qin Dong,&nbsp;Sherry A. Pierce,&nbsp;Xuelin Huang,&nbsp;Elias J. Jabbour,&nbsp;Hagop M. Kantarjian,&nbsp;Guillermo Garcia-Manero","doi":"10.1016/j.leukres.2024.107602","DOIUrl":"10.1016/j.leukres.2024.107602","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107602"},"PeriodicalIF":2.1,"publicationDate":"2024-10-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142503152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study","authors":"Khalis Mustafayev,&nbsp;Eduardo Yepez Guevara,&nbsp;Courtney D. DiNardo,&nbsp;Elias Jabbour,&nbsp;Issa C. Ghayas,&nbsp;Ravin Ratan,&nbsp;Naveen Pemmaraju,&nbsp;Harrys A. Torres","doi":"10.1016/j.leukres.2024.107597","DOIUrl":"10.1016/j.leukres.2024.107597","url":null,"abstract":"","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107597"},"PeriodicalIF":2.1,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142378003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Therapeutic advances for the management of adult T cell leukemia: Where do we stand?","authors":"Hiba El Hajj ,&nbsp;Olivier Hermine ,&nbsp;Ali Bazarbachi","doi":"10.1016/j.leukres.2024.107598","DOIUrl":"10.1016/j.leukres.2024.107598","url":null,"abstract":"<div><div>Adult T cell leukemia (ATL) is an aggressive blood malignancy secondary to chronic infection with the human T cell leukemia virus type I (HTLV-1) retrovirus. ATL encompasses four subtypes (acute, lymphoma, chronic, and smoldering), which exhibit different clinical characteristics and respond differently to various treatment strategies. Yet, all four subtypes are characterized by a dismal long-term prognosis and a low survival rate. While antiretroviral therapy improves overall survival outcomes in smoldering and chronic subtypes, survival remains poor in lymphoma subtypes despite their good response to intensive chemotherapy. Nonetheless, acute ATL remains the most aggressive form associated with profound immunosuppression, chemo-resistance and dismal prognosis. Targeted therapies such as monoclonal antibodies, epigenetic therapies, and arsenic/IFN, emerged as promising therapeutic approaches in ATL. Allogeneic hematopoietic cell transplantation is the only potentially curative modality, alas applicable to only a small percentage of patients. The recent findings demonstrating the expression of the viral oncoprotein Tax in primary ATL cells from patients with acute or chronic ATL, albeit at low levels, and their dependence on continuous Tax expression for their survival, position ATL as a virus-addicted leukemia and validates the rationale of anti-viral treatment strategies. This review provides a comprehensive overview on conventional, anti-viral and targeted therapies of ATL, with emphasis on Tax-targeted therapied in the pre-clinical and clinical settings.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107598"},"PeriodicalIF":2.1,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chemotherapy and allo-HSCT for young patients with aggressive ATL","authors":"Shigeo Fuji","doi":"10.1016/j.leukres.2024.107596","DOIUrl":"10.1016/j.leukres.2024.107596","url":null,"abstract":"<div><div>Adult T-cell leukemia-lymphoma (ATL) is an aggressive malignancy with a poor prognosis, especially for patients with the aggressive subtype. While conventional chemotherapy offers short-term disease control, allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the most promising curative approach for young, transplant-eligible patients. This review focuses on current treatment strategies for aggressive ATL in this specific population. We discuss the rationale for early upfront allo-HSCT following induction chemotherapy. The advent of allo-HSCT using alternative donors, particularly haploidentical HCT, has broadened the applicability of early upfront allo-HSCT in patients with aggressive ATL worldwide. Finally, we address emerging therapies that may improve outcomes in the context of allo-HSCT, paving the way for further advancements in the treatment of aggressive ATL.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107596"},"PeriodicalIF":2.1,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142375648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical relevance of long non-coding RNA in acute myeloid leukemia: A systematic review with meta-analysis","authors":"Priya ,&nbsp;Manoj Garg ,&nbsp;Rashmi Talwar ,&nbsp;Mohit Bharadwaj ,&nbsp;Munindra Ruwali ,&nbsp;Amit Kumar Pandey","doi":"10.1016/j.leukres.2024.107595","DOIUrl":"10.1016/j.leukres.2024.107595","url":null,"abstract":"<div><h3>Background</h3><div>Long noncoding RNAs (lncRNAs) may function as prognostic biomarkers in acute myeloid leukaemia (AML). However, it is still unknown exactly how significant lncRNAs are for the prognosis of AML. With a focus on their prognostic and therapeutic potential, the study aimed to provide a comprehensive review of the literature regarding the role of lncRNAs in AML.</div></div><div><h3>Method</h3><div>Pub Med, The Cochrane Library, Embase, Science Direct, Web of science, Scopus, and Google scholar were searched until November, 2023. Original publications of any type exploring the prognostic and therapeutic potential of lncRNAs in AML patients were included. Heterogeneity and publication bias were examined using the I² test and a funnel plot, respectively. To quantify the relationship between various lncRNA expression in AML patient survival, odds ratios (ORs) or hazards ratios (HRs) with 95 % confidence intervals (CIs) were pooled. Quality of studies was assessed using the Critical Appraisal Checklists for Studies created by the Joanna Briggs Institute (JBI).</div></div><div><h3>Results</h3><div>Twenty-seven studies including 5665 subjects were selected for the final analysis. In patients with AML, abnormal lncRNA expression has been associated with significant worse overall survival (pooled HR = 2.05, 95 % CI = 1.79–2.30, P &lt;0.001), shorter disease-free survival (pooled HR = 2.17, 95 % CI = 1.13–3.22, P&lt; 0.001), and lower complete remission rate (pooled HR = 0.27, 95 % CI = 0.11–0.43, P&lt; 0.001). Poor prognoses have been attributed to increased expression of HOX transcript antisense intergenic RNA (HOTAIR), Promoter Of CDKN1A Antisense DNA Damage Activated RNA (PANDAR), Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1), RP11–222K16.2, Taurine Upregulated Gene 1 (TUG1), Small Nucleolar RNA Host Gene 5 (SNHG5), Growth Arrest Specific 5 (GAS5), and H19 and decreased expression of IGF1R Antisense Imprinted Non-Protein Coding RNA (IRAIN).</div></div><div><h3>Conclusion</h3><div>The prognoses of AML patients are significantly associated with abnormally expressed lncRNAs, which may be used as prognostic indicators for predicting the patient outcomes.</div></div>","PeriodicalId":18051,"journal":{"name":"Leukemia research","volume":"147 ","pages":"Article 107595"},"PeriodicalIF":2.1,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142323970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}